Drug Profile
AP 30663
Alternative Names: AP-30663Latest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator NeuroSearch
- Developer Acesion Pharma
- Class Antiarrhythmics; Cardiovascular therapies; Small molecules
- Mechanism of Action Small conductance calcium-activated potassium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atrial fibrillation
Most Recent Events
- 13 Dec 2023 efficacy and adverse events data from a phase II trial in Atrial fibrillation released by Acesion Pharma
- 28 Sep 2023 No recent reports of development identified for phase-I development in Atrial-fibrillation(In volunteers) in Netherlands (IV)
- 14 Mar 2023 Efficacy and adverse events data from a phase II trial in Atrial fibrillation released by Acesion Pharma